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Abstract Citicoline is the generic name of the pharma-
ceutical substance that chemically is cytidine-50-diph-
osphocholine (CDP-choline), which is identical to the
natural intracellular precursor of phospholipid phosphati-
dylcholine. Following injection or ingestion, citicoline is
believed to undergo quick hydrolysis and dephosphoryla-
tion to yield cytidine and choline, which then enter the
brain separately and are used to resynthesize CDP-choline
inside brain cells. Neuroprotective activity of citicoline has
been repeatedly shown in preclinical models of brain
ischaemia and trauma, but two recent, large, pivotal clini-
cal trials have revealed no benefits in ischaemic stroke and
traumatic brain injury. However, the substance seems to be
beneficial in some slowly advancing neurodegenerative
disorders such as glaucoma and mild vascular cognitive
impairment. This paper critically discusses issues related to
the clinical pharmacology of citicoline, including its
pharmacokinetics/biotransformation and pharmacodynam-
ics/mode of action. It is concluded that at present, there is
no adequate description of the mechanism(s) of the phar-
macological actions of this substance. The possibility
should be considered and tested that, in spite of apparently
fast catabolism, the intact citicoline molecule or the
phosphorylated intermediate products of its hydrolysis,
cytidine monophosphate and phosphocholine, are phar-
macologically active.
Key Points for Decision Makers
Citicoline is chemically identical to CDP-choline,
the natural precursor of the major cell membrane
phospholipid phosphatidylcholine.
Given orally or by injection, citicoline is non-toxic
and very well tolerated.
Preclinical experiments with various models of
central neurodegenerative diseases have shown that
citicoline displays significant neuroprotective
properties.
However, recent large and well-controlled data have
shown no benefit from citicoline in acute ischaemic
stroke and traumatic brain injury.
The pharmacological actions of citicoline in the
central nervous system seem to be pleiotropic and
involve, amongst other things, modulation of some
kinases and sirtuin-1. However, our understanding of
the mechanisms involved is, at most, fragmentary.
1 Introduction
Citicoline is the generic name, or the International Non-
proprietary Name (INN) of cytidine-50-diphosphocholine
(CDP-choline, CDPCho), a pharmaceutical substance that
is chemically identical to the naturally occurring metabo-
lite, which plays crucial role in the synthesis of phospho-
lipids. The work of Kennedy and collaborators in the 1950s
showed that this phosphorylated choline nucleotide is a
precursor of glycerophospholipid phosphatidylcholine (PC)
[1]. PC and its twin compound phosphatidylethanolamine
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(PEt) are the two most abundant phospholipids in eukary-
otic cells, accounting for more than half of the total
phospholipid content in membranes. The pathway of de
novo synthesis of PC, the CDP-choline pathway (Fig. 1),
includes the enzymes cytidine kinase (CK), choline phos-
phate cytidilyltransferase (CCT) and CDP-choline:1,2-
diacylglycerol choline phosphotransferase (CPT) [2].
These enzymes are located intracellularly, in the endo-
plasmic reticulum and cell nucleus [3]. Choline that is used
for synthesis of phosphatidylcholine through the CDP-
choline pathway is derived from transport of exogenous
choline into the cell or from phospholipase D-mediated
turnover of PC [4].
The search for relevant literature—non-clinical as well
as clinical—was performed in the PubMed, Scopus and
Web of Science databases, using the term ‘CDP-choline’,
its variants (‘CDPcholine’, ‘cytidine-diphosphocholine’,
etc.) and ‘citicoline’. Whereas ‘CDP-choline’ designates
the natural metabolite synthesized inside the cells (a sub-
stance of endogenous origin), the term ‘citicoline’ did not
exist until the substance became used as the drug, which
occurred in the 1970s. Notwithstanding, some papers cur-
rently indexed under the term ‘citicoline’ are dated earlier;
some of them (e.g. the paper by Berger and Gimenez [5],
describing crystallization of CDP-choline from yeast)
could be qualified as concerning citicoline (the compound
synthesized exogenously), but others (e.g. the paper by
Ansell and Bayliss [6], reporting on the concentration of
endogenous CDP-choline in the rat brain) undoubtedly
concern CDP-choline (the compound synthesized endoge-
nously). The difference between CDP-choline (synthesized
endogenously) and citicoline (synthesized exogenously) is
not trivial, as will be discussed later.
In the Anglophone medical literature, the use citicoline
as a drug was advocated as early as 1974, by Manaka et al.
[7] from Japan, for the treatment of Parkinson’s disease. A
few years later, the idea of using it as a neuroprotectant
stemmed from the observation, made by Horrocks and
collaborators [8], of the reversibility of phosphotransferase
enzymes in the brain. The first patent for the use of CDP-
ethanolamine, alone or in combination with CDP-choline,
to reverse neurodegenerative diseases was issued in 1981
[9]. Since that time, hundreds of studies concerning various
aspects of the preclinical and clinical pharmacology of
citicoline have been published. Several relevant reviews
have also appeared in high-ranking journals, including at
least five during the last 4 years [10–14]. However, the
subject of citicoline’s mode of action is far from being
clarified. The present review is an attempt to classify the
major issues concerning the neuroprotective properties of
citicoline into three categories: facts, i.e. those that are
solved with an acceptable degree of certainty; doubts, i.e.
those that are likely misinterpreted; and unresolved issues,
i.e. those that remain unexplained. Needless to say, such
classification is subjective: facts, doubts and unresolved
issues are, in many cases, intermingled.
2 Facts
Citicoline displays negligible toxicity. The compound is
quickly catabolized (Fig. 2), and the products arising are
subsequently available for diverse biosynthetic pathways
and ultimately excreted as carbon dioxide. The lack of
acute and chronic toxicity of citicoline has been repeatedly
confirmed in rodents and dogs (see the most recent report
by Schauss et al. [15] and the references quoted therein).
An impressive example is the median lethal dose (LD50) of
an acute single intravenous application of citicoline, which
equals 4,600 and 4,150 mg/kg in mice and rats, respec-
tively. The LD50 for ingested citicoline is even higher at
approximately 8 g/kg in both mice and rats. For compari-
son, in mice, the LD50 of an acute single intravenous dose
Fig. 1 The cytidine-50-diphosphocholine (CDP-choline) pathway of
enzymatic synthesis of phosphatidylcholine. ADP adenosine diphos-
phate, ATP adenosine triphosphate, CCT choline phosphate cytidi-
lyltransferase, CK cytidine kinase, CMP cytidine monophosphate,
CPT CDP-choline:1,2-diacylglycerol choline phosphotransferase,
CTP cytidine triphosphate, DAG 1,2-dicacylglycerol, PC phosphati-
dylcholine, PPi pyrophosphate
Fig. 2 Presumed catabolism of citicoline (Cyt-P-P-Cho) in the rodent
intravascular compartment. In the first step, hydrolysis of the
pyrophosphate bridge takes place. In the second step, cytidine
monophosphate (Cyt-P) and phosphocholine (Cho-P) are dephospho-
rylated to cytidine (Cyt) and choline (Cho), respectively; supposedly,
a large part of the liberated choline is taken up by the liver (which
may explain the unexpectedly low cholinergic toxicity of citicoline)
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of sodium chloride is 645 mg/kg, and that of vitamin C is
518 mg/kg. In a 90-day rat oral toxicity study of
100–1,000 mg/kg daily doses, increases in serum creati-
nine and in renal tubular mineralization, likely caused by
phosphate liberation from citicoline, were found, without
concomitant degenerative or inflammatory reactions.
The usual daily therapeutic dosage of citicoline in
humans is 500–2,000 mg—that is, 7–28 mg/kg in a person
of average bodyweight (70 kg). Data from clinical trials
have corroborated preclinical toxicological findings,
revealing a favourable safety profile, with only a few
reports of adverse events, mostly related to digestive dis-
turbances following oral intake. In adult and elderly stroke
patients, the drug has lacked significant adverse events
(see, for example, the study by Cho and Kim [16] in 4,191
Korean stroke patients), and a meta-analysis of placebo-
controlled trials has shown that the overall frequency of
adverse effects was comparable between groups compris-
ing 1,652 actively treated and 686 placebo-treated subjects
[17]. There are no data concerning the effects of liver or
kidney insufficiency on the safety profile and pharmaco-
kinetics of citicoline although, on the basis of the afore-
mentioned toxicology data, an enhanced threat of
hyperphosphataemia may be predicted in patients with
kidney failure.
Upon administration, citicoline is relatively quickly
catabolized and is the source of choline that appears in the
blood. Administered parenterally or orally, citicoline is
relatively quickly (i.e. within minutes rather than hours)
converted to its cholinergic and pyrimidinergic catabolites.
In the perfused rat liver, citicoline disappeared from the
perfusate within 10 min [18, 19]. Since phosphorylated
substrates are considered unable to penetrate cell mem-
branes, it is usually assumed that cytidine monophosphate
(CMP) and phosphocholine (PCho) yielded from hydroly-
sis of citicoline are further dephosphorylated by phospha-
tases in blood plasma. In agreement with this assumption,
citicoline given orally to rats produced pronounced
increases in plasma cytidine and choline, although it should
be noted that the rise of cytidine was several-fold larger
than that of choline [20]. A recently published paper [21]
reported on the use of a liquid chromatography electro-
spray ionization tandem mass spectrometry (LC–ESI–MS/
MS) method to evaluate the pharmacokinetics of choline in
blood from human volunteers following ingestion of
1,000 mg citicoline tablets. Biphasic concentration–time
curves of choline in plasma have been recorded, with a
large peak of 2 lg/mL at approximately 2 h and a second,
slightly smaller but much broader peak with a maximum at
approximately 24 h following ingestion. Unfortunately, no
data on the initial plasma level of choline were shown,
which makes the whole picture a bit unclear. One older
source reported an arithmetic mean plasma choline level
oscillating around 1.36 lg/mL [22] in a healthy human
subject, and this was confirmed recently [23].
Is citicoline carcinogenic? In a wide variety of cancers,
choline phospholipid metabolism is altered in such a way
that cancer cells display elevated levels of phosphocholine,
as well as total choline-containing compounds [24]. One
may therefore pose a question as to whether increasing
choline exposure doesn’t induce carcinogenesis and/or
accelerate cancer growth. However, choline chloride has
displayed no mutagenic potential when tested in vitro
(using Ames testing, yeast gene conversion, clastogenicity
and sister chromatid exchange) [25], and similar negative
data have been obtained for citicoline [26]. Moreover,
epidemiological data have shown that the associations
between choline intake and cancer—if any—are weak. For
example, Johansson et al. [27] found that elevated plasma
concentrations of choline may be associated with a slightly
increased risk of prostate cancer, but a similar (even
slightly stronger) association has been found for vitamin
B2. On the other hand, Lee et al. [28] did not find any
association between choline (or betaine) intake and the risk
of colorectal cancer, whereas Xu et al. [29] found that
dietary choline intake was inversely associated with breast
cancer risk.
Citicoline is neuroprotective in various animal (pre-
clinical) experimental paradigms. The compound has
offered marked neuroprotection in several in vitro and
in vivo models of acute and chronic brain ischaemic and
neurodegenerative diseases, including brain hypoxia,
ischaemia and intracerebral haemorrhage (reviewed by
Adibhatla and Hatcher [30]), brain and spinal cord trauma
[31], in vitro glutamate excitotoxicity [32, 33] and in vivo
amyloid toxicity [34]. However, the mechanisms of this
neuroprotection are far from being understood.
One major effect of citicoline is believed to be stimu-
lation of the synthesis and increase in the content of brain
phospholipids. Increases in brain phospholipids following
oral administration of citicoline have also been observed in
humans, with use of phosphorous magnetic resonance
spectroscopy [35]. The relevant hypothesis assumes that
the citicoline breakdown products cytidine and choline
enter the brain separately and, inside brain cells, they act as
substrates for resynthesis of CDP-choline. This, in turn, is
believed to result in slowing down of phospholipid
breakdown and acceleration of phospholipid resynthesis
necessary for membrane repair [36]. However, since cit-
icoline is devoid of cholinergic toxicity (see below), a
significant rise in brain choline following therapeutic doses
of citicoline in humans does not seem probable—indeed, a
decrease in choline in the brains of older subjects and no
change in those of younger subjects have been observed
following oral citicoline, with use of proton magnetic
resonance spectroscopy (MRS) [37].
Citicoline for Neuroprotection 187
The other mechanisms suggested to be involved in the
neuroprotective effects of citicoline in stroke models
include prevention of activation of phospholipase A2
(PLA2) [38]. The related effects comprise attenuation of
the increase in hydroxyl radical generation, preventing loss
of cardiolipin (an exclusive inner mitochondrial membrane
phospholipid essential for mitochondrial electron transport,
which is degraded in response to cellular insults and dis-
rupts the mitochondrial respiratory chain). In aged rats, an
increase in the brain level of platelet-activating factor (a
bioactive phospholipid implicated in neuronal excitotoxic
death) has also been noted [39]. In rats, attenuation of
mitogen-activated protein kinases (MAPKs) and caspase
activation have been observed following citicoline
administration [40, 41]. Last, but not least, according to the
most recent report [42], treatment with citicoline has been
found to increase sirtuin-1 (SIRT1) protein levels in cul-
tured neurons, in circulating blood mononuclear cells and
in the brain. This effect seems to be of critical importance
for neuroprotection in experimental stroke because sirtinol,
a specific inhibitor of SIRT1 which, by itself, does not
influence infarct volume, has been shown to abolish the
neuroprotection offered by citicoline. Citicoline displayed
a potent synergistic effect with resveratrol (which is known
to be a SIRT1 activator), leading to a 60 % reduction in the
experimental infarct volume in rats when both drugs were
used in doses that were individually ineffective. Moreover,
citicoline was ineffective in SIRT1 knock-out homozygotic
mice subjected to focal brain ischaemia. However, detailed
mechanistic explanations for all of these effects are lack-
ing. For example, there is no explanation as to how citic-
oline administration leads to attenuation of MAPK activity
and increases sirtuin-1 protein content in brain tissues; in
particular, does the drug act extracellularly, or is resyn-
thesis of CDP-choline inside brain cells a prerequisite?
Citicoline is not beneficial in patients with stroke and
traumatic brain injury. Positive results of preclinical
studies with animal models of neurodegenerative diseases
have prompted clinical trials with citicoline as a treatment
for human brain diseases. Whereas several previous small
clinical studies had achieved promising results, two recent
large randomized multicenter trials—the COBRIT (Citic-
oline Brain Injury Treatment) trial performed in 1,213
patients with traumatic brain injury [43], and the interna-
tional, randomized, multicentre, placebo-controlled
sequential ICTUS (International Citicoline Trial on Acute
Stroke) trial performed in 2,298 patients with moderate-to-
severe acute ischaemic stroke [44]—led to the conclusion
that citicoline is not efficacious in these clinical settings.
The negative outcomes of these studies were deemed sur-
prising and prompted a few comments, which focused
mostly, although not exclusively, on methodological
aspects of the evaluation of the clinical effects of the drug
[45–47]. What was not commented on was the lack of a
mechanistic explanation for the putative neuroprotective
properties of citicoline.
Citicoline treatment seems beneficial in some chronic
neurodegenerative diseases. Some recent data are sugges-
tive that prolonged intake of citicoline, given orally or by
injection, may be significantly effective in certain slowly
developing neurodegenerative diseases. One is glaucoma,
currently considered a neurodegenerative disease, which
involves the entire central visual pathway. In glaucoma
patients with moderate visual defects, citicoline treatment
improved retinal function and neural conduction, and
continuation of treatment for 2–8 years significantly slo-
wed, stabilized or even improved glaucomatous visual
dysfunction [48, 49]. The other is mild vascular cognitive
impairment. In the open IDEALE (Studio di Intervento nel
Decadimento Vascolare Lieve) study [50], oral citicoline
taken for up to 9 months significantly improved the Mini-
Mental State Examination score and positively influenced
mood; the latter effect could have been related to increases
in noradrenaline and dopamine levels, which would be
expected on the basis of animal experiments (see the paper
by Rejdak et al. [51] and the references cited therein).
Also, it has recently been shown that in sub-acute
ischaemic cerebrovascular disease, administration of cit-
icoline in an intravenous dose of 2,000 mg for 5 or 10 days
improves functional independence and reduces the burden
of care [52]. The uniqueness of citicoline may lie not only
in its negligible toxicity and virtual lack of side effects but
also in the fact that it appears to deliver a significant sub-
jective improvement and mood-enhancing effect.
3 Doubts
Where is citicoline catabolized? While it seems reasonable
to assume that, at least in rodents, citicoline given sys-
temically is quickly hydrolysed and further dephosphoryl-
ated, the particulars of this decomposition process are
uncertain. Does it take place in blood plasma or in other
location(s)? Of note is that, following injection or ingestion
of citicoline in the rat, the increase in plasma cytidine was,
on a molar basis, several times larger than the concomitant
increase in plasma choline [20]. What happened to the
‘surplus’ choline? Was it taken up by the liver? Does the
several-fold ‘domination’ of the cytidine increase over the
choline increase provide an explanation for the lack of
cholinergic toxicity of citicoline versus the toxic effects of
equimolar choline (see below)?
How is citicoline catabolized? In humans, an oral
challenge with citicoline was accompanied by an increase
in plasma uridine instead of cytidine [53]. In this last study,
the participants took oral citicoline doses of up to 4 g (still
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much less per kilogram of bodyweight than the doses used
in most rodent experiments), and significant dose-related
increases in blood plasma uridine were observed. The data
resembled the rat data reported previously by the same
laboratory [20] in that the magnitude of the choline
increases was several times smaller than the magnitude of
the pyrimidine increase. Choline increments obtained after
2 or 4 g doses were comparable, on a molar basis, to those
seen after similar doses of choline chloride, although the
peaks were delayed by one or more hours. The authors
failed, however, to detect any significant quantities of
cytidine in human blood, either before or after citicoline
intake. They interpreted this finding as evidence that the
human gastrointestinal tract and liver quantitatively trans-
form cytidine liberated from citicoline to circulating uri-
dine. Would this indicate that hydrolysis of citicoline to
CMP and PCho and consecutive dephosphorylations of
these products to cytidine and choline occur almost
immediately, followed by conversion of cytidine to uri-
dine? But why is the final effect—namely, an increase in
circulating choline—delayed by one or more hours?
Resynthesis of CDP-choline in the brain following cit-
icoline intake and the pharmacodynamics of citicoline. It is
usually assumed that following citicoline intake, cytidine
and choline enter brain cells separately and are used for
intracellular synthesis of CDP-choline [36]. For example,
in a recent paper, Ramos-Cabrer et al. [54] stated ‘‘It is
believed that when citicoline is exogenously administered
as sodium salt, it is hydrolysed into choline and cytidine to
be re-synthesized later in the brain…’’. These statements
seem to imply that resynthesis of citicoline from cytidine
and choline in the brain is the only event—or at least the
most important event—of systemic citicoline application.
At this point, the difference between citicoline (syn-
thesized exogenously) and CDP-choline (synthesized
endogenously) acquires its key importance, for at least
three reasons. First, it must be appreciated that only a
minor fraction of the choline dose administered as citico-
line enters the brain. Tolvanen et al. [55] investigated the
biodistribution and biokinetics of [11C]choline (a radio-
pharmaceutical used for oncological positron emission
tomography [PET] studies) in rats and humans following
intravenous injection. They found that the highest uptake of
the tracer was by the kidney, lung and adrenal glands,
whereas the brain cortex and cerebellum were the organs
taking up less than 0.1 % of the tracer dose. Second,
stimulation following citicoline intake of at least two other
major synthetic pathways of choline in the brain, one
leading to betaine (an important donor of methyl groups)
and the other leading to acetylcholine (an important CNS
neurotransmitter), should also be taken into account [56].
Third, the ischaemic heart is the source of increased cho-
line in the blood of patients with an acute coronary
syndrome related to coronary plaque instability [57].
Moreover, the authors mention small unpublished pilot
studies in which elevated levels of whole blood choline
were also found in patients with stroke or cerebral
ischaemia in combination with advanced plaques in the
carotid artery. It is reasonable to assume that degradation
of membrane phospholipids and elevation of blood choline
levels occur in all cases of brain ischaemia, i.e. ischaemic
stroke. Is there any difference between the metabolic
effects of choline increases in plasma consequential to
citicoline intake and those resulting from a heart attack or
stroke?
Why were preclinical results with citicoline for stroke
not reproduced in the clinical setting? The systematic
review and meta-analysis of data obtained with preclinical
models of embolic stoke [58] provided evidence that cit-
icoline does indeed deliver some neuroprotection; how-
ever, the effect is stronger for infarct volume reduction and
more limited for neurological outcome. The authors con-
cluded that factors shown to be important for translation
into human studies are multiple-dose administration, large
infarct size and/or neurological deficit. However, the most
important cause of the irreproducibility of preclinical
results in a clinical setting may be the use of excessively
large doses of citicoline in most animal experiments. For
example, in a series of papers authored by Savci and col-
laborators (see the paper by Eyigor et al. [59] and the
references quoted therein), various cardiovascular and
endocrine effects of large, although subtoxic, doses of
citicoline (0.5–2 g/kg) given intravenously were described.
Among them were an increase in blood pressure and large
rises in plasma levels of catecholamines and several pitu-
itary hormones, including vasopressin and oxytocin. Evi-
dence of histaminergic system involvement in the
responses to citicoline has also been presented [60]. Can
these effects be of potential benefit, e.g. in hypovolaemic
shock (as suggested by Savci et al. [61]), or are they instead
an early sign of toxicity? (On the other hand, it would be of
importance to find an explanation for the observation that
in rats—both normotensive and haemorrhagic—these
massive doses of citicoline increased blood pressure,
whereas no such effect occurred following equivalent doses
of either cytidine or choline.)
Similar doubts may be raised against the recent report
by Gutie´rrez-Ferna´ndez et al. [62], who compared the
effects of citicoline (1,000 mg/kg intraperitoneally) and
recombinant tissue plasminogen activator [rt-PA] (5 mg/kg
intravenously) in a rat model of embolic stroke. The
problem with this paper was that whereas the rt-PA dose
used per kg of bodyweight was 5 to 8 times the dose used
in the treatment of human embolic stroke (0.6–1.1 mg/kg
intravenously; see Wardlaw et al. [63]), the citicoline dose
was 15 to 30 times the dose used in clinical trials of
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citicoline in stroke. The rationale for investigating the
effects of injecting citicoline in doses corresponding to
30–150 g per person (assuming an average human body-
weight of 70 kg) is doubtful.
4 Unresolved Issues
Why is citicoline so much less toxic than choline? The
acute toxicity of citicoline and choline after oral and
intravenous application was compared by Agut et al. [64].
These authors concluded that CDP-choline given either
orally or intravenously did not cause any cholinergic
intoxication in the treated groups, whereas such toxic
effects were observed after administration of an equimolar
dose of choline. Apparently, CDP-choline given by the oral
or intravenous route yields toxicological consequences that
are different from those yielded by choline. A mechanistic
interpretation of the substantially lower toxicity of citico-
line compared with that of choline is lacking to date.
Can intact citicoline be delivered orally? Yashima et al.
[65] used citicoline doubly-labelled with carbon-14 at the
methyl groups of choline and tritium at C5 of pyrimidine,
and obtained evidence of CDP-choline being broken down
in the intestine, resulting in release of choline and cytidine,
likely due to the actions of intestinal esterases and pyro-
phosphatases. However, the authors concluded that ‘‘these
split compounds as well as the original CDP-choline may
be absorbed from the intestinal mucosa as such’’. Appar-
ently, they could not rule out the possibility that following
oral intake, some fraction of intact citicoline is absorbed.
Is citicoline a prodrug or an active compound? The
consequences of the assumed fast hydrolysis and sub-
sequent dephosphorylation of citicoline after injection or
oral intake are usually interpreted in terms of a prodrug,
which is administered in an inactive or less than fully
active form and is subsequently metabolically converted
(bioactivated) to the active pharmacological agents, cyti-
dine and choline. However, one may assume that the
reverse is true, i.e. the most active form is unhydrolysed
(intact) citicoline, whereas cytidine and choline are its
pharmacologically less active metabolites. Although the
prodrug concept clearly prevails in the scientific literature,
several observations may indicate that intact citicoline
molecules, or perhaps CMP and/or PCho intermediates,
display their own activities, which are different from and/or
more potent than the actions of cytidine and choline.
One reason for not discarding the idea of intact citico-
line being significantly neuroprotective is the magnitude of
the protective effect of citicoline in vitro versus in vivo.
Neuroprotective effects in vitro occurred upon exposure of
retinal cells or brain neurons to citicoline concentrations as
low as submicromolar to micromolar [66, 67], whereas in
the in vivo (animal) experiments, the minimal doses nec-
essary to produce appreciable neuroprotection were within
the range of 0.3–1 g/kg [68], an amount that could be
equivalent to 0.6–2 mmol/kg, assuming even distribution
throughout the body. Thus, citicoline seems to be a neu-
roprotectant that acts weakly in vivo but is much more
potent in vitro.
The other reason concerns the activity of liposomal cit-
icoline. A few studies have indicated that in experimental
ischaemic stroke, liposomal formulations of citicoline are
significantly more neuroprotective (i.e. by means of
decreasing the ischaemic infarct volume) than equivalent
doses of free citicoline (see, for example Fresta and Puglisi
[69, 70] and Adibhatla et al. [69, 70]). The most recent
study of this kind [54] indicated that liposomal citicoline is
more neuroprotective than the equivalent intravenous dose
of the free drug which, in turn, is more neuroprotective than
the equivalent intraperitoneal dose. Although other expla-
nations may be speculated upon, the aforementioned result
is compatible with the idea that intact citicoline is phar-
macologically more active than its metabolites.
Does intact citicoline modulate some kinases? Interest-
ing observations have been reported on the modulation by
citicoline of the activity/expression of some protein kinases
involved in neuronal death—namely, MAPKs—in the
postischaemic brain [40] and extracellular signal-regulated
kinase 1/2 (ERK1/2) in the rat retina after kainic acid (KA)
treatment [71]. Modulation of activity of cellular kinases
and, in particular, members of the ERK/MAPK family,
occurs through transduction of extracellular signals [72,
73]. Perhaps the neuroprotective actions of citicoline are
exerted not by its hydrolysis products but by the unhy-
drolysed molecules acting extracellularly as signalling
molecules. In this context, one should consider the possi-
bility of binding of citicoline to plasma proteins such as
albumin. Albumin binding has been reported for cytidine
[74] and also for sphingosylphosphorylcholine [75], a
compound remotely similar to citicoline. If intact citicoline
binds to albumin, its hydrolysis could be retarded and its
action as a signalling molecule could be prolonged.
5 Conclusions
In spite of the negative results of recent pivotal studies in
acute ischaemic stroke and traumatic brain injury, there is
continuing interest in the neuroprotective properties of
citicoline. The drug is non-toxic, and numerous preclinical
data support the view that it displays neuroprotective
properties. However, no adequate mechanistic explanation
for these observations has ever been provided.
The most frequently presented explanation for the neu-
roprotective effects of citicoline on the brain is based on
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the assumption that it is a prodrug which, following
injection or ingestion, is sequentially hydrolysed and
dephosphorylated, finally, to cytidine (or uridine in
humans) and choline. Then these two metabolites sepa-
rately enter the brain tissues and are used to resynthesize
CDP-choline, which exerts neuroprotection intracellularly
by supporting biosynthesis of cellular phospholipids. An
alternative explanation—i.e. that unhydrolysed citicoline,
or perhaps phosphocholine and/or cytidine monophosphate,
are pharmacologically active metabolites of citicoline—has
never been considered.
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